Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acrolein and other α,β-unsaturated carbonyl compounds are small, electrophilic, unsaturated aldehydes and ketones resulting from environmental exposure (e.g., combustion of organic materials) and endogenous lipid peroxidation during oxidative stress. They are not classical biological targets (such as receptors or enzymes), but rather, are highly reactive toxicants that covalently modify nucleophilic sites (especially cysteine thiols) in proteins and DNA via Michael-type addition. This leads to protein dysfunction, cellular stress, neurotoxicity (nerve terminal damage), inflammation, and in some cases, genotoxicity and carcinogenesis. Because these molecules disrupt many molecular pathways through non-specific covalent modification, they are generally considered harmful reactive species rather than druggable therapeutic targets
Drugs like Mesna work as nucleophilic thiol donors, inactivating acrolein by covalent scavenging (neutralization of Michael acceptors)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acrolein and other α,β-unsaturated carbonyl compounds.